Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by DryBoneson Mar 27, 2019 11:54pm
203 Views
Post# 29546105

RE:For the pro's... PPPS question...

RE:For the pro's... PPPS question...PLI has the technology for eliminating pathogens in the blood supply.  They spent years developing it for Cruzfeld-Jacobs disease (mad cow prions).  They had as close to 100% reduction iin prions as it is possible to get.  At the time the UK blood supply was tainted by people who carried the pathogen but were not yet symptomatic and were donating blood.  There was no test for carriers - none.  .

The UK health service could not use their own blood supply, and were getting blood products from elsewhere.  The national health service wanted to filter all blood supplies suing PLI technology.  A parliamentary committee turned down the idea and PLI's original venture ended.  

PlI stock went to 8 cents.
Bullboard Posts